Climb Bio (CLYM) Company Overview

NEW YORK , Jan. 2, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Climb Bio, Inc. (NASDAQ: CLYM) on behalf of the company's shareholders.  The investigation seeks to determine whether Climb Bio's directors breached their fiduciary duties in connection with recent corporate actions.

Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D.

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine®, Enbrel®, Adcetris®, Tecfidera®, Alprolix®, Eloctate® and Spinraza®. As a CEO, he has successfully guided both private and public companies from development to commercialization and has overseen multiple successful mergers.

Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trial s in Systemic Lupus Erythematosus (SLE) and Immune Thrombocytopenia (ITP) with First Patients Dosed Targeted for 1H25 Cash runway through 2027 Expected to Enable Delivery of Key Value Inflection Points Virtual Investor Event to be Held at 12:00 p.m. ET Today WELLESLEY HILLS, Mass.